Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Clin Chim Acta. 2018 Aug;483:25-32. doi: 10.1016/j.cca.2018.03.034. Epub 2018 Apr 1.
LINC00152, a novel long noncoding RNA (lncRNA), was identified as an oncogene involved various cancers. This study was designed to explore the clinical significance and prognosis role of LINC00152.
Eligible studies were recruited by a systematic search in PubMed, Web of Science, and Embase up to August 23, 2017. Odds ratios (ORs), hazard ratios (HRs) and 95% confidence interval (95% CI) were pooled using Review Manager 5.3 and STATA 12.0.
A total of 10 studies with 913 patients were included to evaluate the association between LINC00152 expression and clinicopathological factors, overall survival (OS) and disease-free survivals (DFS). The results indicated that the expression level of LINC00152 was positively correlated with tumor size (OR = 5.19, 95% CI: 2.33-11.52, p < .0001), TNM stage (OR = 3.12, 95% CI: 1.77-5.51, p < .0001) and lymph node metastasis (OR = 3.41, 95% CI: 2.13-5.48, p < .00001). Moreover, elevated LINC00152 could predict unfavorable OS with pooled HR of 1.66 (95% CI: 1.29-2.13, p < .0001) and poor DFS (HR = 2.13, 95% CI: 1.39-3.25, p = .0005) in cancer patients.
LINC00152 was correlated with advanced clinicopathological features and poor prognosis as a novel predictive biomarker in various cancers.
LINC00152 是一种新型的长链非编码 RNA（lncRNA），被认为是参与多种癌症的癌基因。本研究旨在探讨 LINC00152 的临床意义和预后作用。
通过系统搜索 PubMed、Web of Science 和 Embase，检索截至 2017 年 8 月 23 日的相关研究。使用 Review Manager 5.3 和 STATA 12.0 软件对纳入的研究进行数据分析。
共纳入 10 项研究，包含 913 例患者，评估 LINC00152 表达与临床病理因素、总生存期（OS）和无病生存期（DFS）的关系。结果表明，LINC00152 的表达水平与肿瘤大小（OR=5.19，95%CI：2.33-11.52，p<0.0001）、TNM 分期（OR=3.12，95%CI：1.77-5.51，p<0.0001）和淋巴结转移（OR=3.41，95%CI：2.13-5.48，p<0.00001）呈正相关。此外，LINC00152 水平升高可预测癌症患者的不良 OS（HR=1.66，95%CI：1.29-2.13，p<0.0001）和DFS（HR=2.13，95%CI：1.39-3.25，p=0.0005）。
LINC00152 与先进的临床病理特征和不良预后相关，可作为各种癌症的新型预测生物标志物。
